Sbir phase II: development of genetically modified sterile insects for biocontrol
Ended Cooperative Agreement Awarded Last action
- Award ID
- 2200356
- Recipient
-
Novoclade, Inc. UEI D6SBFKJGXLV3
- Awarding agency
-
National Science Foundation
- Obligated
- $1,019,941
Award facts
- Assistance listing
- 47.084 NSF Technology, Innovation, and Partnerships
- Completion date
- Funding
-
- $1,003,941.00 Federal
- $16,000.00 Non-federal
- Place of performance
- St Paul, MN 55114, USA
Award details come from USAspending.gov.
Description
- Abstract
- The broader impact of this small business innovative research (SBIR) phase II project will be to improve insect control with minimal chemical impact. Due to their impact on human health and losses to agriculture, insects pose threats upwards of $10 billion/year to the world economy. Current methods of insect control using chemical insecticides are somewhat effective but pose a grave threat to the environment. The company is developing a genetic-based insect control technology. This approach can be very effective, have minimal environmental impact and be cost effective to implement. The technology is broadly applicable to any sexually reproducing organism, which could enable applications beyond the first intended target of spotted wing drosophila. Likely future applications include control of insects important for public health, such as mosquitoes or ticks, other agricultural pests, and invasive species. The proposed project is designed to use genetics to solve issues posed by chemical insecticides and issues associated with broad adoption of sterile insect techniques: (I) sorting of male only insects, (II) laborious release processes and (III) non-scalable operation. The objective of this project is to create a prototype and verify its ability to control the initial target insect, spotted wing drosophila. The project will also investigate the robustness of the developed genetic system for commercial production. This research project will expand scientific knowledge of insect transgenesis and their use for biocontrol. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $16,000 | $0 | |
| Amendment | $16,000 | $16,000 | |
| Original award | $971,941 | $0 |
Quick answers
Who received award 2200356?
2200356 was awarded to Novoclade, Inc. by National Science Foundation on May 1, 2022.
How much is award 2200356 worth?
$1,019,941 has been obligated on 2200356: $1,003,941 in federal funding and $16,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award